JP2021534762A5 - - Google Patents
Info
- Publication number
- JP2021534762A5 JP2021534762A5 JP2021510019A JP2021510019A JP2021534762A5 JP 2021534762 A5 JP2021534762 A5 JP 2021534762A5 JP 2021510019 A JP2021510019 A JP 2021510019A JP 2021510019 A JP2021510019 A JP 2021510019A JP 2021534762 A5 JP2021534762 A5 JP 2021534762A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence numbers
- sequence
- numbers
- isolated polynucleotide
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/103050 | 2018-08-29 | ||
| CN2018103050 | 2018-08-29 | ||
| CN2019083918 | 2019-04-23 | ||
| CNPCT/CN2019/083918 | 2019-04-23 | ||
| PCT/CN2019/103215 WO2020043152A1 (en) | 2018-08-29 | 2019-08-29 | Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534762A JP2021534762A (ja) | 2021-12-16 |
| JP2021534762A5 true JP2021534762A5 (enExample) | 2022-09-01 |
| JP7490915B2 JP7490915B2 (ja) | 2024-05-28 |
Family
ID=69643948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510019A Active JP7490915B2 (ja) | 2018-08-29 | 2019-08-29 | 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11932698B2 (enExample) |
| EP (1) | EP3844282A4 (enExample) |
| JP (1) | JP7490915B2 (enExample) |
| KR (1) | KR102879284B1 (enExample) |
| CN (1) | CN112639102B (enExample) |
| AU (1) | AU2019327913A1 (enExample) |
| CA (1) | CA3111087A1 (enExample) |
| IL (1) | IL281098A (enExample) |
| SG (1) | SG11202101773WA (enExample) |
| TW (1) | TW202024330A (enExample) |
| WO (1) | WO2020043152A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| IL268110B2 (en) * | 2017-01-26 | 2024-01-01 | Sangamo Therapeutics Inc | B-cell engineering |
| EP3715368A1 (en) * | 2019-03-28 | 2020-09-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells |
| US20230183336A1 (en) * | 2019-08-14 | 2023-06-15 | Modmab Therapeutics Inc. | Antibodies that bind to lrp5 proteins and methods of use |
| CN110964750A (zh) * | 2019-11-13 | 2020-04-07 | 沣潮医药科技（上海）有限公司 | 携带基因元件组合的嵌合抗原受体细胞文库、制备和筛选方法及用途 |
| US12264190B2 (en) * | 2020-04-24 | 2025-04-01 | Astrazeneca Ab | Compositions and methods of treating cancer with chimeric antigen receptors |
| WO2021226289A2 (en) * | 2020-05-05 | 2021-11-11 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
| GB202006820D0 (en) * | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| JP2023532347A (ja) * | 2020-06-29 | 2023-07-27 | セル メディカ，インコーポレイテッド | キメラ抗原受容体の緊張性シグナル伝達を減少させる方法および組成物 |
| KR102309543B1 (ko) | 2020-08-04 | 2021-10-07 | 주식회사 셀렌진 | 메소텔린에 특이적으로 결합하는 항-메소텔린 키메릭 항원 수용체 |
| GB202012181D0 (en) * | 2020-08-05 | 2020-09-16 | Autolus Ltd | Chimeric receptor |
| WO2022037562A1 (en) * | 2020-08-17 | 2022-02-24 | Nanjing Legend Biotech Co., Ltd. | Engineered immunoresponsive cells and uses thereof |
| US20240050569A1 (en) * | 2020-12-18 | 2024-02-15 | Bioardis, Llc | Mesothelin binding molecules and uses thereof |
| US20240034807A1 (en) * | 2021-02-16 | 2024-02-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to mesothelin polypeptides |
| WO2022232277A1 (en) * | 2021-04-27 | 2022-11-03 | TCR2 Therapeutics Inc. | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH |
| CN116635406B (zh) * | 2021-05-26 | 2024-07-30 | 细胞基因股份公司 | 一种包括抗间皮素scFv的嵌合抗原受体及其用途 |
| CN117441020A (zh) * | 2021-06-08 | 2024-01-23 | 南京驯鹿生物技术股份有限公司 | 一种增强型嵌合抗原受体（car）细胞的制备及其应用 |
| WO2023020472A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Mesothelin-targetting antibodies and uses thereof in cancer therapies |
| CN115746123B (zh) * | 2021-09-02 | 2026-07-07 | 广东菲鹏制药股份有限公司 | TGFβRII突变体及其应用 |
| CN115724942A (zh) * | 2021-09-02 | 2023-03-03 | 广东菲鹏制药股份有限公司 | TGFβRII活性改造突变体及其应用 |
| CN114015720A (zh) * | 2021-09-29 | 2022-02-08 | 昆明市延安医院 | 具有靶向高强度杀瘤活性的Mesothelin嵌合抗原受体修饰的T细胞的制备方法 |
| EP4412651A4 (en) * | 2021-10-06 | 2025-10-08 | Wistar Inst | BISPECIFIC T CELL ACTIVATING AGENTS TARGETING FSHR AND METHODS OF USE IN CANCER THERAPEUTICS |
| WO2023064876A1 (en) * | 2021-10-14 | 2023-04-20 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| MX2024003887A (es) | 2021-10-14 | 2024-07-09 | Arsenal Biosciences Inc | Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. |
| WO2023070126A1 (en) * | 2021-10-22 | 2023-04-27 | Regents Of The University Of Minnesota | Genetically engineered t cell receptors |
| EP4461747A4 (en) * | 2022-01-06 | 2026-04-15 | Oricell Therapeutics Co Ltd | ANTIGEN-BINDING PROTEIN TARGETTING MSLN AND ITS USE |
| CN114560949B (zh) * | 2022-03-07 | 2023-09-26 | 中国人民解放军空军军医大学 | 一种具有增强car-t细胞抗肿瘤能力的嵌合抗原受体、d-car-t细胞及其应用 |
| CN116284409A (zh) * | 2022-07-08 | 2023-06-23 | 上海优替济生生物医药有限公司 | Gpc3 car-t细胞及其在制备治疗癌症的药物中的用途 |
| US20260224618A1 (en) * | 2022-10-28 | 2026-08-06 | Oricell Therapeutics Co., Ltd. | Antigen-binding protein targeting msln |
| AU2023371779B2 (en) * | 2022-11-02 | 2025-11-27 | Cellengene Inc | Chimeric antigen receptor with increased affinity for mesothelin and use thereof |
| CN116019939A (zh) * | 2022-11-24 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 靶向msln的分子探针以及用途 |
| WO2024192534A1 (en) * | 2023-03-23 | 2024-09-26 | National Research Council Of Canada | Anti-mesothelin (msln) single domain antibodies and therapeutic constructs |
| CN118109416B (zh) * | 2023-03-30 | 2024-11-22 | 广州百吉生物制药有限公司 | 功能增强型工程化免疫细胞及其制备和应用 |
| TW202504914A (zh) * | 2023-06-14 | 2025-02-01 | 美商默沙東有限責任公司 | 嵌合抗原受體及其用途 |
| WO2024259305A1 (en) * | 2023-06-14 | 2024-12-19 | The Broad Institute, Inc. | Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof |
| CN119708251A (zh) * | 2023-09-27 | 2025-03-28 | 北京大学 | 一种利用cd27逆转t和car-t细胞pd1信号的工程化细胞方法 |
| CN118147105B (zh) * | 2024-05-09 | 2024-08-02 | 西宝生物科技（上海）股份有限公司 | 一种蔗糖磷酸化酶的高效制备方法 |
| CN119859615A (zh) * | 2024-12-31 | 2025-04-22 | 广州安捷生物医学技术有限公司 | 一种靶向成纤维细胞激活蛋白的car-msc细胞及其制备方法和应用 |
| WO2026152120A2 (en) | 2025-01-13 | 2026-07-16 | HCW Biologics, Inc. | Chimeric polypeptides and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| EP1625159B1 (en) * | 2003-05-20 | 2011-03-02 | The University Court Of The University Of Glasgow | Materials and methods relating to g-protein coupled receptor oligomers |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| US9416190B2 (en) * | 2012-09-27 | 2016-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| CN102875685B (zh) | 2012-09-29 | 2013-12-25 | 郑骏年 | 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途 |
| WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| SI2997141T1 (sl) | 2013-05-13 | 2023-04-28 | Cellectis | CD19 specifični himerni antigenski receptor in njegova uporaba |
| CA2912375C (en) | 2013-05-13 | 2023-03-14 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| WO2015188141A2 (en) | 2014-06-06 | 2015-12-10 | Memorial Sloan-Kettering Cancer Ceneter | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| US10577417B2 (en) * | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3273994B1 (en) * | 2015-03-27 | 2021-12-01 | University of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
| CN104877032B (zh) * | 2015-06-26 | 2018-12-11 | 中国医学科学院血液病医院（血液学研究所） | Cd33特异性嵌合抗原受体及其应用 |
| AU2016317936A1 (en) | 2015-09-04 | 2018-03-08 | Tocagen Inc. | Recombinant vectors comprising 2A peptide |
| CN110352068A (zh) * | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| US11541076B2 (en) * | 2017-01-13 | 2023-01-03 | Celdara Medical, Llc | Chimeric antigen receptors targeting TIM-1 |
-
2019
- 2019-08-29 KR KR1020217009330A patent/KR102879284B1/ko active Active
- 2019-08-29 CA CA3111087A patent/CA3111087A1/en active Pending
- 2019-08-29 CN CN201980055889.4A patent/CN112639102B/zh active Active
- 2019-08-29 AU AU2019327913A patent/AU2019327913A1/en not_active Abandoned
- 2019-08-29 EP EP19854280.5A patent/EP3844282A4/en active Pending
- 2019-08-29 WO PCT/CN2019/103215 patent/WO2020043152A1/en not_active Ceased
- 2019-08-29 US US17/270,970 patent/US11932698B2/en active Active
- 2019-08-29 TW TW108131105A patent/TW202024330A/zh unknown
- 2019-08-29 JP JP2021510019A patent/JP7490915B2/ja active Active
- 2019-08-29 SG SG11202101773WA patent/SG11202101773WA/en unknown
-
2021
- 2021-02-24 IL IL281098A patent/IL281098A/en unknown